FDA Panel Unanimously Recommends Approval for Novartis' CAR-T Therapy CTL019
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell | Nature Medicine
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials
FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars | Biosimilars Law Bulletin
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Novartis nabs much-needed new nod for slow-growing breast cancer drug Kisqali | Fierce Pharma
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials - ScienceDirect
FDA staffers like Sandoz' biosimilarity data for copy of Amgen's Enbrel | Fierce Pharma
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
Racing toward a historic CAR-T approval, Novartis wins unanimous FDA panel backing | Fierce Pharma
Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon - Cytotherapy
FDA Panel Votes Unanimously in Favor of First CAR-T Cancer Therapy | RAPS
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy | Journal of Law, Medicine & Ethics | Cambridge Core
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites | Cell Death & Disease
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy | Nature Communications
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials - ScienceDirect
